this embedded ecr award aims to advance the overall objectives of the hsi program. additionally, this funding opportunity specifically aims to:

1. support ecrs as they develop embedded research roles and programs that advance the methods of embedded research, build embedded research capacity within health system organizations and mentor emerging embedded researchers, and generate evidence-informed solutions for high-priority challenges within health system organizations.
2. contribute to building a strong cadre of embedded researchers across the country that will play a role in transformative health system improvement that advances the quadruple aim and health equity.
3. support the development of career pathways for a diverse cadre of embedded researchers within canada’s health system.

the eureka smart cluster for advanced manufacturing has launched its 6^th call for proposals for research & development (r&d) projects.

smart is a flexible, industry-driven eureka cluster program whose aim is to promote innovative, collaborative, international and close-to-market r&d projects in advanced manufacturing.

open to:

• small and medium-sized enterprises (smes);
• large enterprises and industries;
• universities;
• research organizations; and
• others.

sector of focus:

advanced manufacturing with a focus on:

• advanced manufacturing processes;
• customer-based manufacturing;
• digital, virtual and efficient companies;
• intelligent and adaptive manufacturing systems;
• person-machine collaboration; and
• sustainable manufacturing.

deadline to submit a project outline (optional but recommended): january 30, 2023 (11:00am cet)

for more information, please contact jill sherman at intl.research@lakeheadu.ca.

the specific objectives of this funding opportunity are:

• to enhance evidence regarding the adaptation and successful implementation of evidence-based interventions in preventing or reducing exposure to one or more common non-communicable disease (ncd) risk factors of city environments;
• to increase understanding of key barriers and facilitators (including contextual factors such as poverty, racism, ethnic discrimination, sex/gender differences) to intervention access, uptake, and effectiveness across demographic groups;
• to improve capacity for implementation research on ncd prevention in cities;
• to foster the incorporation of interventions into local, regional or national health policies and programs, including their scale-up and sustainability, with a focus on equitable outcomes; and
• to support implementation research teams that actively engage partners (i.e., decision makers, indigenous peoples, community groups, and service delivery partners) as an integral part of the entire research process.

the als canada-brain canada clinical research fellowship 2023 is designed to support the further training of a clinician to develop the skills necessary to become a specialist in als and provides training in clinical or basic research relevant to the field. specialized training of young mds in both clinical care and research skills related to als is crucial to building better clinical infrastructure across canada.

one fellowship of up to $200,000 cad total is available for up to two years. the funds awarded through this fellowship will be utilized to support the stipend/salary of the awardee.

• track 1 – implementation: funding up to $750,000 per year for four to five years for the establishment of a global centre

• track 2 – design: funding up to $100,000 per year for one to two years for coordination and preliminary research efforts aiming to foster future global centres proposals

he fy23 defense appropriations act is anticipated to provide funding for the alsrp to support development of effective treatments for amyotrophic lateral sclerosis (als).  the managing agent for the anticipated funding opportunities is the cdmrp at the u.s. army medical research and development command (usamrdc).

the fy23 alsrp funding opportunity announcements for the following award mechanisms are posted on the grants.gov website. 

pilot clinical trial award – preproposal due april 13, 2023

independent investigators at or above the level of assistant professor (or equivalent)

• supports exploratory clinical trials of novel therapeutics to demonstrate feasibility and inform the design of more advanced trials in amyotrophic lateral sclerosis (als).
• must support a clinical trial and may not be used for preclinical research studies.
• biomarkers specific to the intervention must be incorporated into the trial design.
• preliminary data are required.
• new for fy23:  applications are expected to name at least one community partner (e.g., person with als, family member or caregiver, representative of a community-based organization) who will provide advice and consultation throughout the planning and implementation of the clinical trial.
• clinical care tier: 
• applications not investigating a novel therapeutic but proposing a clinical trial to optimize established als clinical care, may submit under the clinical care tier.
• examples of efforts that will be supported include:
• optimization of respiratory care strategies
• improvements to approved devices and assistive technologies
• specific symptom management strategies
• telemedicine strategies
• pre-application submission is required; full application submission is by invitation only.
• the maximum allowable funding for the entire period of performance is $2,000,000 for direct costs.
• clinical care tier:  the maximum allowable funding for the entire period of performance is $1,000,000 for direct costs.
• indirect costs may be proposed in accordance with the institution’s negotiated rate agreement.
• the maximum period of performance is 3 years.

https://cdmrp.health.mil/funding/alsrp

therapeutic development award – preproposal due april 13, 2023

independent investigators at all academic levels (or equivalent)

• supports secondary preclinical validation and investigational new drug (ind)-enabling studies of therapeutics for als.
• preliminary data are required, including therapeutic efficacy in at least one als-relevant model system.
• mechanism-specific predictive/cohort-selective, target engagement, or pharmacodynamic biomarker development, in parallel to the main therapeutic effort, is a critical component.  if mechanism-specific biomarkers are already available or currently in development, how the existing biomarkers will improve trial design, patient selection, and efficiency or interpretation of the proposed als therapeutic approach must be described.
• pre-application submission is required; full application submission is by invitation only.
• •the maximum allowable funding for the entire period of performance is $1,500,000 for direct costs.
• •indirect costs may be proposed in accordance with the institution’s negotiated rate agreement.
• •the maximum period of performance is 3 years.

clinical biomarker development award – preproposal due april 13, 2023

independent investigators at all academic levels (or equivalent) 

• supports development or improvement of clinical biomarkers to enrich clinical trials in als.
• biomarker analysis can be relevant to a specific therapeutic or a specific als subtype and does not have to broadly apply to all patients.
• a description of the biomarker category and intended use in als therapeutic development, including regulatory considerations for use in als clinical trials or clinical practice, is an important component.
• examples of efforts that will be supported include:

• using patient-based resources to link biosamples to rigorous molecular data
• collecting and analyzing biospecimens as a companion to an anticipated/ongoing clinical trial
• correlating clinical trial-related data (e.g., biosample analyses, imaging, or epidemiological data) with clinical outcomes/ responses to therapies
• strategies to better measure disease progression, including development or use of digital biomarkers

pre-application submission is required; full application submission is by invitation only.

• the maximum allowable funding for the entire period of performance is $750,000 for direct costs.
• indirect costs may be proposed in accordance with the institution’s negotiated rate agreement.
• the maximum period of performance is 2 years.

therapeutic idea award – preproposal due april 13, 2023

independent investigators at all academic levels (or equivalent) 

• supports highly innovative, hypothesis-driven preclinical therapeutic development in als.
• projects focusing primarily on investigating als pathophysiology, without consideration of therapeutic development, are outside the scope of this award mechanism.
• preliminary data are not required.
• early-career investigators are encouraged to apply.
• biomarker option:  applications that include development of biomarkers in parallel to the main therapeutic effort and that meet criteria outlined in the program announcement, will qualify for a higher level of funding.

pre-application submission is required; full application submission is by invitation only.

• the maximum allowable funding for the entire period of performance is $600,000 for direct costs.
• biomarker option:  the maximum allowable funding for the entire period of performance is $750,000 for direct costs.
• indirect costs may be proposed in accordance with the institution’s negotiated rate agreement.
• the maximum period of performance is 2 years.

a pre-application is required and must be submitted through the electronic biomedical research application portal (ebrap) at https://ebrap.org prior to the pre-application deadline.  all applications must conform to the final funding opportunity announcements available for downloading from the grants.gov website.  the application package containing the required forms for each award mechanism will also be found on grants.gov.  a listing of all cdmrp and other usamrdc extramural funding opportunities can be obtained on the grants.gov website by performing a basic search using cfda number 12.420.

for email notification when announcements are released, subscribe to program-specific news and updates under “email subscriptions” on the ebrap homepage at https://ebrap.org.  for more information about the alsrp or other cdmrp-administered programs, please visit the cdmrp website (https://cdmrp.health.mil).

point of contact:

cdmrp help desk
301-682-5507
help@ebrap.org

please contact jill sherman for more information at intl.research@lakeheadu.ca

the fy23 defense appropriations act is to provide funding for the erp to support research to understand the mechanisms of post-traumatic epilepsy (pte) and associated comorbidities to improve quality of life, especially in service members, veterans, and caregivers.  the managing agent for the anticipated funding opportunities is the cdmrp at the u.s. army medical research and development command (usamrdc).

the fy23 erp funding opportunity announcements for the following award mechanisms are posted on the grants.gov website. 

funding opportunities-fy23 erp, congressionally directed medical research programs (cdmrp) (health.mil)

new for fy22: leveraging research award – letter of intent due may 19, 2023

the pi may be an investigator at any career level.

• intent:  to support research that leverages ongoing or completed research studies for which pte was not an original focus and to provide support to expand the research to develop such a focus and increase our understanding of pte.  the project may include basic, translational, and/or clinical research studies. 
• clinical trials are not allowed under this funding opportunity.
• the proposed study must be associated with an ongoing or completed research effort in which pte is/was not an existing research priority and for which addition of cohorts, outcomes, assessments, or analysis specific to pte would be scientifically justified increase our understanding of pte.
• the maximum allowable funding for the entire period of performance is $250,000 for direct costs.
• the maximum period of performance is 3 years

idea development award – letter of intent due may 19, 2023

• level i:  intended to support early-career investigators ranging from the postdoctoral level (e.g., research associate, fellows, residents, or equivalent) to within 3 years of their first independent faculty position (or equivalent)
• level ii:  investigators at any career level may be named by the organization as the principal investigator (pi) on the application.
• the pi can be from any field or discipline but must demonstrate suitable experience relevant to the proposed research.
• intent:  to solicit novel, innovative research that has the potential to increase our understanding of post-traumatic epilepsy (pte) to improve quality of life, especially in service members, veterans, and/or their care partners.  the work should innovatively challenge existing research paradigms or exhibit high levels of creativity.

the fy23 erp idea development award offers two levels of funding dependent upon the level of experience of the pi:

•level i is intended to support early-career investigators.  requires a mentor as part of the application.

•level ii is intended to support independent investigators.  applicants can be from any field or discipline.  study teams are expected to demonstrate experience in both traumatic brain injury (tbi) and epilepsy.

preliminary data are not required; however, evidence demonstrating the research team’s ability to execute the chosen model of tbi and record subsequent seizure is required, if applicable.

clinical trials are not allowed under this funding opportunity.

level i:

•the maximum allowable funding for the entire period of performance is $450,000 for direct costs.

•the maximum period of performance is 3 years.

level ii:

•the maximum allowable funding for the entire period of performance is $650,000 for direct costs.

•the maximum period of performance is 3 years.

research partnership award – letter of intent due may 19, 2023

the initiating pi and partnering pi(s) may be investigators at any career level. 

the initiating pi and named partnering pi(s) can be from any field or discipline but must demonstrate suitable experience relevant to the proposed research.

• intent:  to create an avenue to support new or existing collaborative research partnerships between/among investigators to address a research problem or question in a manner that would be unachievable through separate efforts.  it is expected that investigators utilize their distinct but complementary perspectives to synergistically address a central problem or question critical to pte research and those living with pte, their families, and/or their care partners. 

a proposed project in which a partner merely supplies tissue or access to patients will not meet the intent of this award mechanism.

clinical trials are not allowed under this funding opportunity.

•the maximum allowable funding for the entire period of performance is $1,200,000 for direct costs.

•the maximum period of performance is 3 years.

virtual post-traumatic epilepsy research center faculty award – letter of intent due may 19, 2023

early-career investigators and investigators new to the pte field 

• introduction to the erp virtual p-terc:  the p-terc is a unique, interactive virtual research center providing intensive mentoring, national networking, collaborations, and a peer group for new pte investigators.  the overarching goal of the virtual p-terc is to develop successful, highly productive pte researchers in a collaborative research and career development environment to enhance quality and expand quantity of the pte research field.
• intent of this funding mechanism:  to solicit faculty members to join the virtual p-terc in order to advance pte research through the development of early-career investigators and investigators new to the pte field.
• important aspects of this award mechanism include:
• focus on the pi’s research and career development.
• support for research projects with an emphasis on discovery that investigate questions across the pte research spectrum (biology/etiology, prevention, diagnosis/
• detection, prognosis, treatment, and quality of life).
• requires a career guide as part of the application
• preliminary data are not required; however, evidence demonstrating the research team’s ability to execute the chosen model of tbi and record subsequent seizure is required, if applicable.
• the maximum allowable funding for the entire period of performance is $525,000 for direct costs.
• the maximum period of performance is 3 years.

a pre-application is required and must be submitted through the electronic biomedical research application portal (ebrap) at https://ebrap.org prior to the pre-application deadline.  all applications must conform to the final funding opportunity announcements available for downloading from the grants.gov website.  the application package containing the required forms for each award mechanism will also be found on grants.gov.  a listing of all cdmrp and other usamrdc extramural funding opportunities can be obtained on the grants.gov website by performing a basic search using cfda number 12.420.

for email notification when announcements are released, subscribe to program-specific news and updates under “email subscriptions” on the ebrap homepage at https://ebrap.org.  for more information about the erp or other cdmrp-administered programs, please visit the cdmrp website (https://cdmrp.health.mil).

point of contact:

cdmrp help desk
301-682-5507
help@ebrap.org

for more information, please contact jill sherman at intl.research@lakeheadu.ca.